NASDAQ:TGTX - TG Therapeutics Inc common stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.15 -0.05 (-0.41 %)
(As of 07/22/2018 04:00 PM ET)
Previous Close$12.15
Today's Range$11.95 - $12.45
52-Week Range$7.25 - $17.35
Volume919,956 shs
Average Volume999,476 shs
Market Capitalization$947.82 million
P/E Ratio-6.36
Dividend YieldN/A
Beta1.15
TG Therapeutics Inc common stock logoTG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Debt-to-Equity RatioN/A
Current Ratio3.51
Quick Ratio3.51

Price-To-Earnings

Trailing P/E Ratio-6.36
Forward P/E Ratio-5.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales6,318.81
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book12.79

Profitability

EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-87,025.00%
Return on Equity-170.83%
Return on Assets-125.58%

Miscellaneous

Employees75
Outstanding Shares78,010,000
Market Cap$947.82

TG Therapeutics Inc common stock (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics Inc common stock's stock symbol?

TG Therapeutics Inc common stock trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics Inc common stock's earnings last quarter?

TG Therapeutics Inc common stock (NASDAQ:TGTX) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.15. The biopharmaceutical company earned $0.04 million during the quarter, compared to analysts' expectations of $0.04 million. TG Therapeutics Inc common stock had a negative return on equity of 170.83% and a negative net margin of 87,025.00%. View TG Therapeutics Inc common stock's Earnings History.

What price target have analysts set for TGTX?

4 brokerages have issued 12 month price objectives for TG Therapeutics Inc common stock's stock. Their predictions range from $27.00 to $33.00. On average, they expect TG Therapeutics Inc common stock's share price to reach $29.3333 in the next year. This suggests a possible upside of 141.4% from the stock's current price. View Analyst Ratings for TG Therapeutics Inc common stock.

What is the consensus analysts' recommendation for TG Therapeutics Inc common stock?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics Inc common stock in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about TG Therapeutics Inc common stock stock?

Here are some recent quotes from research analysts about TG Therapeutics Inc common stock stock:
  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (5/10/2018)
  • 2. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
  • 3. HC Wainwright analysts commented, "TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui’s BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors." (1/8/2018)

Who are some of TG Therapeutics Inc common stock's key competitors?

Who are TG Therapeutics Inc common stock's key executives?

TG Therapeutics Inc common stock's management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 52)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 36)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

Has TG Therapeutics Inc common stock been receiving favorable news coverage?

Media headlines about TGTX stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TG Therapeutics Inc common stock earned a daily sentiment score of 0.06 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are TG Therapeutics Inc common stock's major shareholders?

TG Therapeutics Inc common stock's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Mycio Wealth Partners LLC (0.09%), North Star Investment Management Corp. (0.03%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own TG Therapeutics Inc common stock stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics Inc common stock.

Which institutional investors are buying TG Therapeutics Inc common stock stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Mycio Wealth Partners LLC, North Star Investment Management Corp. and Xact Kapitalforvaltning AB. View Insider Buying and Selling for TG Therapeutics Inc common stock.

How do I buy shares of TG Therapeutics Inc common stock?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics Inc common stock's stock price today?

One share of TGTX stock can currently be purchased for approximately $12.15.

How big of a company is TG Therapeutics Inc common stock?

TG Therapeutics Inc common stock has a market capitalization of $947.82 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics Inc common stock employs 75 workers across the globe.

How can I contact TG Therapeutics Inc common stock?

TG Therapeutics Inc common stock's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics Inc common stock (NASDAQ TGTX)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  418 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics Inc common stock and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.